152 related articles for article (PubMed ID: 25591119)
1. Kinase inhibitor profile for human nek1, nek6, and nek7 and analysis of the structural basis for inhibitor specificity.
Moraes EC; Meirelles GV; Honorato RV; de Souza Tde A; de Souza EE; Murakami MT; de Oliveira PS; Kobarg J
Molecules; 2015 Jan; 20(1):1176-91. PubMed ID: 25591119
[TBL] [Abstract][Full Text] [Related]
2. Human Nek6 is a monomeric mostly globular kinase with an unfolded short N-terminal domain.
Meirelles GV; Silva JC; Mendonça Yde A; Ramos CH; Torriani IL; Kobarg J
BMC Struct Biol; 2011 Feb; 11():12. PubMed ID: 21320329
[TBL] [Abstract][Full Text] [Related]
3. A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases.
Belham C; Roig J; Caldwell JA; Aoyama Y; Kemp BE; Comb M; Avruch J
J Biol Chem; 2003 Sep; 278(37):34897-909. PubMed ID: 12840024
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of Nek6 protein kinase, a potential human homolog of NIMA histone H3 kinase.
Hashimoto Y; Akita H; Hibino M; Kohri K; Nakanishi M
Biochem Biophys Res Commun; 2002 May; 293(2):753-8. PubMed ID: 12054534
[TBL] [Abstract][Full Text] [Related]
5. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
Shafique S; Bibi N; Rashid S
J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of two evolutionarily conserved murine kinases (Nek6 and nek7) related to the fungal mitotic regulator, NIMA.
Kandli M; Feige E; Chen A; Kilfin G; Motro B
Genomics; 2000 Sep; 68(2):187-96. PubMed ID: 10964517
[TBL] [Abstract][Full Text] [Related]
7. Characterization of hNek6 interactome reveals an important role for its short N-terminal domain and colocalization with proteins at the centrosome.
Vaz Meirelles G; Ferreira Lanza DC; da Silva JC; Santana Bernachi J; Paes Leme AF; Kobarg J
J Proteome Res; 2010 Dec; 9(12):6298-316. PubMed ID: 20873783
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle regulation by the NEK family of protein kinases.
Fry AM; O'Regan L; Sabir SR; Bayliss R
J Cell Sci; 2012 Oct; 125(Pt 19):4423-33. PubMed ID: 23132929
[TBL] [Abstract][Full Text] [Related]
9. Differential control of the NIMA-related kinases, Nek6 and Nek7, by serum stimulation.
Minoguchi S; Minoguchi M; Yoshimura A
Biochem Biophys Res Commun; 2003 Feb; 301(4):899-906. PubMed ID: 12589797
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.
Yun T; Qin T; Liu Y; Lai L
ChemMedChem; 2016 Apr; 11(7):713-7. PubMed ID: 27061239
[TBL] [Abstract][Full Text] [Related]
11. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
Yun T; Qin T; Liu Y; Lai L
Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Reichelt A; Bailis JM; Bartberger MD; Yao G; Shu H; Kaller MR; Allen JG; Weidner MF; Keegan KS; Dao JH
Eur J Med Chem; 2014 Jun; 80():364-82. PubMed ID: 24793884
[TBL] [Abstract][Full Text] [Related]
13. Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6.
De Donato M; Righino B; Filippetti F; Battaglia A; Petrillo M; Pirolli D; Scambia G; De Rosa MC; Gallo D
Sci Rep; 2018 Oct; 8(1):16047. PubMed ID: 30375481
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel inhibitors for Nek6 protein through homology model assisted structure based virtual screening and molecular docking approaches.
Srinivasan P; Chella Perumal P; Sudha A
ScientificWorldJournal; 2014; 2014():967873. PubMed ID: 24587765
[TBL] [Abstract][Full Text] [Related]
16. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
[TBL] [Abstract][Full Text] [Related]
18. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
[TBL] [Abstract][Full Text] [Related]
19. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
[TBL] [Abstract][Full Text] [Related]
20. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
